Werfen Life Group, SA
http://www.werfenlife.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Werfen Life Group, SA
Five Multiple Sclerosis R&D Updates From ECTRIMS
With the virtual doors about to close on the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting, Scrip takes a look at some of the highlights, including data for Merck KGaA and Sanofi’s new BTK inhibitors and research showing the impact of MS therapies on COVID-19 vaccine response.
Novartis Scores Another CSU Success With Remibrutinib
The Swiss group believes that remibrutinib, as well as its investigational IgE antibody ligelizumab, will complement standard of care Xolair and help it build a strong franchise for chronic spontaneous urticaria.
Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Company Information
- Industry
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
-
Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
-
- Accriva Diagnostics
- Accumetrics
- ITC Nexus Holding Company
- Leventon
- Werfen